SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Pierre Le Moyne d'Iberville Synthetic CCD — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientPierre Le Moyne d'Iberville
Date of birth1661-07-16
IdentifiersMRN HR-ET014-SYN-TD; SSN (made up) 000-14-7260
Document date2026-11-01
AuthorMarguerite Delacroix-Boateng, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Reason for Visit

New patient visit for recurrent fevers with chills after naval service in malaria-endemic areas, and an expected tropical deployment: history, examination, malaria testing, quantitative G6PD, and an infectious diseases (travel medicine) referral. Concerns: He fears another attack of fever at sea, where he would be far from a laboratory and responsible for the squadron; He must have every vaccine and certificate that entry to French Guiana and the islands requires before the squadron sails. [S]

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Medications

MedicationFrequencyRouteDatesStatusEvidence
Chloroquine phosphate 500 mg tablet: 1,000 mg (two tablets) at once, then 500 mg at 6, 24 and 48 hours; take with food1,000 mg, then 500 mg at 6, 24 and 48 hours (2,500 mg salt in total)Oral route1705-03-03 to 1705-03-05completedS
Primaquine phosphate 26.3 mg tablet (15 mg base): two tablets (30 mg base) by mouth daily with food for 14 days30 mg base once daily for 14 daysOral route1705-03-03 to 1705-03-16completedS
Atovaquone-proguanil 250 mg/100 mg tablet: one tablet daily with food, starting one to two days before entering a malaria area, daily there, and for seven days after leavingonce daily from 1 to 2 days before until 7 days after the malaria areasOral route1705-10-13on-holdS
Azithromycin 500 mg tablet: one tablet daily for up to three days for severe travelers' diarrhea (standby supply)once daily for up to 3 days if neededOral route1705-10-13on-holdS
Primaquine phosphate 26.3 mg tablet (15 mg base): two tablets (30 mg base) daily with food for 14 days, starting when he leaves the malaria areas (terminal prophylaxis)30 mg base once daily for 14 days after leaving the malaria areasOral route1705-10-13on-holdS

Procedures

ProcedureDatesStatusEvidence
Advance care planning conversation, about 20 minutes1705-04-21 to 1705-04-21completedS
Incision and drainage of a cutaneous abscess of the right forearm under local anesthesia, with wound culture1705-06-09 to 1705-06-09completedS

Immunizations

DateVaccineStatusEvidence
1705-04-21Tdap vaccinecompletedS
1705-07-28Yellow fever vaccine, live, single dose; certificate (ICVP) issued, valid from ten days after vaccinationcompletedS
1705-07-28Hepatitis A vaccine, adult, dose 1 of 2completedS
1705-07-28Typhoid Vi polysaccharide vaccinecompletedS
1705-07-28Hepatitis B vaccine (HepB-CpG), dose 1 of 2completedS
1705-10-13Hepatitis B vaccine (HepB-CpG), dose 2 of 2completedS
1705-10-13Influenza vaccine, inactivated, trivalent, preservative-freecompletedS

Past Medical History

Historical biography with true dates. These events are not part of the synthetic care timeline.

Historical dateHistoryEvidence
late 1701An illness at sea, nature not recorded, that forced him to put in at port on a voyage to the Gulf of Mexico about three and a half years before intakeD (CLM-0007)
1702 onwardRecurrent attacks of illness over the past three years, described by his biographer as malaria, that kept him from planned voyagesD (CLM-0008)

Family History

No family medical history is documented in the logged sources. Family history of real relatives is recorded only from documented or retrospective sources and is never synthesized.

Health Concerns

ConcernStatusEvidence
He fears another attack of fever at sea, where he would be far from a laboratory and responsible for the squadronactiveS
He must have every vaccine and certificate that entry to French Guiana and the islands requires before the squadron sailsactiveS

Assessment

Most recent measures: Hemoglobin [Mass/volume] in Blood 14.1 on 1705-10-13; Leukocytes [#/volume] in Blood by Automated count 5.6 on 1705-02-17; Platelets [#/volume] in Blood by Automated count 236 on 1705-10-13; Sodium [Moles/volume] in Serum or Plasma 139 on 1705-02-17; Potassium [Moles/volume] in Serum or Plasma 4.1 on 1705-02-17; Creatinine [Mass/volume] in Serum or Plasma 0.98 on 1705-02-17; Glucose [Mass/volume] in Serum or Plasma 92 on 1705-02-17; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 34 on 1705-02-17; Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 29 on 1705-02-17; Bilirubin.total [Mass/volume] in Serum or Plasma 0.7 on 1705-03-31; Glucose-6-Phosphate dehydrogenase [Enzymatic activity/mass] in Red Blood Cells 11.8 on 1705-02-17; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1700)/1.73 sq M 98 on 1705-02-17; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 0 on 1705-04-21; Total score [AUDIT-C] 3 on 1705-04-21; Cholesterol [Mass/volume] in Serum or Plasma 192 on 1705-04-21; Cholesterol in HDL [Mass/volume] in Serum or Plasma 52 on 1705-04-21; Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 116 on 1705-04-21; Triglyceride [Mass/volume] in Serum or Plasma 120 on 1705-04-21 [S]

Strengths and supports: engagement in care [S]

Problems

ProblemClinical statusVerificationCodeProvenance
Recurrent episodes of fever with shaking chills and drenching sweats, three in the past two years, each beginning months after naval service in malaria-endemic areas; the first diagnosed as malaria abroad on a blood smear with the species not recorded and treated with chloroquine alone, the later two treated with chloroquine without testing; the last ended six weeks before intake; afebrile and well at intake; cause not established at intake; infectious diseases consultation requestedresolvedconfirmed R50.9S — Synthetic presenting problem anchored to his documented recurrent attacks of illness called malaria; superseded by the diagnosis at the infectious diseases consultation.
Relapsing Plasmodium vivax malaria: P. vivax DNA detected by PCR in blood drawn between attacks, with negative smears and rapid antigen test; after three relapses treated without antirelapse therapy; normal quantitative G6PDresolvedconfirmed B51.9S — Synthetic modern diagnosis made at the infectious diseases consultation, linked to his documented recurrent attacks of illness called malaria; the species and the PCR result are synthetic.
Pre-travel care for a naval deployment, expected to sail early next year, to French Guiana and the French Antilles: yellow fever vaccination required for entry to French Guiana, malaria prevention, dengue, chikungunya and typhus prevention by vector avoidance, food and water safety, and travel vaccinesactiveconfirmed Z71.84S — Synthetic modern counterpart of his documented preparation of a tropical campaign in 1705.
Small cutaneous abscess of the right forearm, about 2 cm, from a wooden splinter in the dockyard, without fever, spreading cellulitis or systemic signs; drained, without antibiotics; methicillin-susceptible Staphylococcus aureus on culture; resolvedresolvedconfirmed L02.413S — Synthetic acute problem; not a historical claim.

Results

DateMeasureValueUnitReference rangeFlagProvenance
1705-02-17Hemoglobin [Mass/volume] in Blood13g/dL13.2-17.1 g/dLLowS
1705-02-17Leukocytes [#/volume] in Blood by Automated count5.610*3/uL3.4-9.6 10*3/uLNormalS
1705-02-17Platelets [#/volume] in Blood by Automated count14110*3/uL150-400 10*3/uLLowS
1705-02-17Sodium [Moles/volume] in Serum or Plasma139mmol/L136-145 mmol/LNormalS
1705-02-17Potassium [Moles/volume] in Serum or Plasma4.1mmol/L3.5-5.1 mmol/LNormalS
1705-02-17Creatinine [Mass/volume] in Serum or Plasma0.98mg/dL0.74-1.35 mg/dLNormalS
1705-02-17Glucose [Mass/volume] in Serum or Plasma92mg/dL70-99 mg/dLNormalS
1705-02-17Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma34U/L7-52 U/LNormalS
1705-02-17Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma29U/L13-39 U/LNormalS
1705-02-17Bilirubin.total [Mass/volume] in Serum or Plasma1.1mg/dL0.3-1.2 mg/dLNormalS
1705-02-17Glucose-6-Phosphate dehydrogenase [Enzymatic activity/mass] in Red Blood Cells11.8U/g{Hb}7-20.5 U/g{Hb}NormalS
1705-02-17Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1700)/1.73 sq M98mL/min/{1.73_m2}60 or moreNormalS
1705-03-31Hemoglobin [Mass/volume] in Blood13.6g/dL13.2-17.1 g/dLNormalS
1705-03-31Platelets [#/volume] in Blood by Automated count21210*3/uL150-400 10*3/uLNormalS
1705-03-31Bilirubin.total [Mass/volume] in Serum or Plasma0.7mg/dL0.3-1.2 mg/dLNormalS
1705-10-13Hemoglobin [Mass/volume] in Blood14.1g/dL13.2-17.1 g/dLNormalS
1705-10-13Platelets [#/volume] in Blood by Automated count23610*3/uL150-400 10*3/uLNormalS
1705-04-21Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]0{score}S
1705-04-21Total score [AUDIT-C]3{score}S
1705-04-21Cholesterol [Mass/volume] in Serum or Plasma192mg/dL<=199 mg/dLNormalS
1705-04-21Cholesterol in HDL [Mass/volume] in Serum or Plasma52mg/dL>=40 mg/dLNormalS
1705-04-21Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation116mg/dLBelow 130NormalS
1705-04-21Triglyceride [Mass/volume] in Serum or Plasma120mg/dL<=149 mg/dLNormalS

Social History

Vital Signs

DateMeasureValueUnitProvenance
1705-02-17Body height175cmS
1705-02-17Body weight68.4kgS
1705-02-17Body mass index (BMI) [Ratio]22.3kg/m2S
1705-02-17Systolic blood pressure124mm[Hg]S
1705-02-17Diastolic blood pressure78mm[Hg]S
1705-02-17Heart rate70/minS
1705-02-17Respiratory rate14/minS
1705-02-17Body temperature36.7CelS
1705-02-17Oxygen saturation in Arterial blood by Pulse oximetry98%S
1705-03-03Body height175cmS
1705-03-03Body weight68.6kgS
1705-03-03Body mass index (BMI) [Ratio]22.4kg/m2S
1705-03-03Systolic blood pressure122mm[Hg]S
1705-03-03Diastolic blood pressure76mm[Hg]S
1705-03-03Heart rate68/minS
1705-03-03Respiratory rate14/minS
1705-03-03Body temperature36.6CelS
1705-03-03Oxygen saturation in Arterial blood by Pulse oximetry98%S
1705-03-31Body height175cmS
1705-03-31Body weight69kgS
1705-03-31Body mass index (BMI) [Ratio]22.5kg/m2S
1705-03-31Systolic blood pressure122mm[Hg]S
1705-03-31Diastolic blood pressure78mm[Hg]S
1705-03-31Heart rate66/minS
1705-03-31Respiratory rate14/minS
1705-03-31Body temperature36.6CelS
1705-03-31Oxygen saturation in Arterial blood by Pulse oximetry98%S
1705-07-28Body height175cmS
1705-07-28Body weight69.4kgS
1705-07-28Body mass index (BMI) [Ratio]22.7kg/m2S
1705-07-28Systolic blood pressure124mm[Hg]S
1705-07-28Diastolic blood pressure78mm[Hg]S
1705-07-28Heart rate66/minS
1705-07-28Respiratory rate14/minS
1705-07-28Body temperature36.7CelS
1705-07-28Oxygen saturation in Arterial blood by Pulse oximetry98%S
1705-10-13Body height175cmS
1705-10-13Body weight69.2kgS
1705-10-13Body mass index (BMI) [Ratio]22.6kg/m2S
1705-10-13Systolic blood pressure122mm[Hg]S
1705-10-13Diastolic blood pressure76mm[Hg]S
1705-10-13Heart rate64/minS
1705-10-13Respiratory rate14/minS
1705-10-13Body temperature36.6CelS
1705-10-13Oxygen saturation in Arterial blood by Pulse oximetry98%S
1705-04-21Body height175cmS
1705-04-21Body weight69.2kgS
1705-04-21Body mass index (BMI) [Ratio]22.6kg/m2S
1705-04-21Systolic blood pressure120mm[Hg]S
1705-04-21Diastolic blood pressure76mm[Hg]S
1705-04-21Heart rate64/minS
1705-04-21Respiratory rate14/minS
1705-04-21Body temperature36.6CelS
1705-04-21Oxygen saturation in Arterial blood by Pulse oximetry98%S
1705-06-09Body height175cmS
1705-06-09Body weight69.3kgS
1705-06-09Body mass index (BMI) [Ratio]22.6kg/m2S
1705-06-09Systolic blood pressure124mm[Hg]S
1705-06-09Diastolic blood pressure78mm[Hg]S
1705-06-09Heart rate70/minS
1705-06-09Respiratory rate14/minS
1705-06-09Body temperature36.8CelS
1705-06-09Oxygen saturation in Arterial blood by Pulse oximetry98%S

Encounters

DatePurposeStatusProvenance
1705-02-17New patient visit for recurrent fevers with chills after naval service in malaria-endemic areas, and an expected tropical deployment: history, examination, malaria testing, quantitative G6PD, and an infectious diseases (travel medicine) referralfinishedS
1705-03-03Two-week follow-up and infectious diseases consultation: PCR result and radical curefinishedS
1705-03-31Six-week review after chloroquine and primaquine: blood count, adverse effects, relapse surveillancefinishedS
1705-07-28Pre-travel visit: yellow fever, hepatitis A, hepatitis B and typhoid vaccines, and the travel planfinishedS
1705-10-13Pre-departure review: no relapse, malaria chemoprophylaxis, vector, food and water precautions, standby treatment, and the plan on returnfinishedS
1705-04-21Periodic adult preventive visitfinishedS
1705-06-09Same-day sick visit for a skin abscess of the right forearmfinishedS

Plan of Treatment

InterventionStatusGuidelineProvenance
Infectious diseases (travel medicine) consultation in two weeks to establish the cause of the recurrent fevers, advise on antirelapse treatment, and plan pre-travel care for the deploymentcompletedGL-CDC-MAL-TX-2026, GL-IDSA-TRAVEL-2006S
Malaria testing between attacks: thick and thin blood smears, rapid antigen test, and Plasmodium species PCR sent to the reference laboratory; quantitative G6PD activity before any primaquine; blood count, kidney and liver testscompletedGL-CDC-MAL-TX-2026S
Fever action plan: a blood smear the same day for any fever, at home, at sea or after travel; carry a card stating his malaria historycompletedGL-CDC-MAL-TX-2026, GL-YB-MAL-2026S
Chloroquine for the blood stage (1,000 mg salt, then 500 mg at 6, 24 and 48 hours) and primaquine 30 mg base daily for 14 days for radical cure, with the normal G6PD result; blood count and bilirubin after the course; report dark urine, breathlessness or blue lipscompletedGL-CDC-MAL-TX-2026S
Pre-travel plan for French Guiana and the Antilles: one dose of yellow fever vaccine with the certificate, hepatitis A, hepatitis B if not immune, typhoid; atovaquone-proguanil chemoprophylaxis for malaria areas; repellent, permethrin-treated clothing, screened or air-conditioned quarters and bed nets against mosquitoes, fleas, lice and mites; food and water precautions with standby azithromycin; primaquine terminal prophylaxis after leaving the malaria areas, and a malaria test for any fever after returncompletedGL-YB-YF-2026, GL-CDC-FG-2026, GL-YB-MAL-2026, GL-YB-DENGUE-2026, GL-YB-RICK-2026, GL-YB-TD-2026, GL-IDSA-TRAVEL-2006S

Goals

GoalTargetStatusOutcomeProvenance
No further malaria relapse in the six months after radical cure1705-10-13completedNo fever in the seven months since finishing primaquineS
All required and recommended travel vaccines given, with a valid yellow fever certificate, at least ten days before departure1705-10-13completedYellow fever, hepatitis A dose 1, hepatitis B two-dose series, typhoid and influenza vaccines given; certificate validS
Knows to have a malaria test the same day for any fever, during travel and for months after return1705-03-31completedCarries a fever card and explained the plan back correctlyS

Functional Status

Mental Status